The medicine Retevmo contains Selpercatinib, a kinase inhibitor used in the treatment of patients who have metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer (namely RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer). Retevmo capsules are supplied in 40 mg and 80 mg for oral administration.